Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Clinical Factors of Prognosis in Surgical Series: A Focus on Smoking Status
Author
Howard (Jack) West, MD

In my last post I wrote about the prognostic value of molecular markers like EGFR and K-Ras that have generally been studied in patients with advanced NSCLC and treated with EGFR inhibitors, but these studies looked at prognosis in patients with early stage NSCLC who underwent surgery. These studies also provided some interesting results on the prognostic value of some clinical variables as well.

The Japanese surgical series of 397 patients with resected adenocarcinomas (abstract here) reported several associations of survival with clinical variables, as shown in the figures below:

Japanese lung adenos clinical variables (Click to enlarge)

Some of these findings are very intuitive. In the top right, we see that patients with stage I adenocarcinomas have a far superior survival to patients with higher stage cancers. Since staging is designed as a method to predict prognosis, these results corroborate what we'd expect. I've also written a prior post about more poorly differentiated cancers being associated with a worse prognosis than better differentiated cancers, as is shown in the bottom right panel. And there has been a growing collection of evidence that, as a population, women with lung cancer have a more favorable prognosis, stage for stage, than men (see prior post), as shown in the panel on the lower left.

In this retrospective review, the patients who had never smoked had a significantly better survival, as shown in the upper left (and, just to reiterate a striking result, 48% of the patients in this Japanese series were never-smokers). This report excluded patients who were known to have started an EGFR inhibitor, so this improved survival presumably represents a more favorable underlying cancer biology, and/or a lower risk of dying from some other smoking-related health risks. And the US-based trial from Memorial-Sloan Kettering in NYC showed the same association of better survival in never-smoking patients with resected NSCLC:

Smoking status and OS in surg pts from MSKCC

Both the Japanese and the Memorial studies also showed, as I described in my prior post, that the survival of patients with a tumor that has an EGFR mutation was significantly better than the survival in patients without an EGFR mutation, and this was correlated with smoking history. In fact, the Japanese study showed that the more significant a patient's history of smoking, the lower the chance of them having an EGFR mutation and the higher the chance of them having a tumor with a K-Ras and/or p53 mutations, which are both associated with a worse prognosis:

Japanese mutations correlated with smoking status

Interestingly, the association of a gradually decreasing likelihood of an EGFR mutation with increasing smoking status was first reported from -- you guessed it -- Memorial Sloan Kettering. This goes back a few years, and it focused on patients with advanced NSCLC, but it showed that while never-smokers were the group with the highest frequency of EGFR mutations, the smoking population wasn't all the same, but rather had a clear association of greatest smoking history with lowest likelihood of an EGFR mutation:

MSKCC Pham smoking history and EGFR

Overall, I think it's important to recognize that the favorable results among never-smokers may be primarily driven by the association of never-smoker lung cancer with the more favorable biology of an EGFR mutation. But it's also important to recognize that separating patients into ever-smokers and never-smokers is an oversimplification.

As is the distinction between clinical predictors and molecular predictors, since they are clearly associated with each other. Multiple different factors go into the mix of trying to predict the biology of a cancer, and we use all the information we can get in trying to individualize our recommendations.

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi and welcome to Grace.  Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
 Hi arm2966, Welcome to…
By JanineT GRACE … on
Joanne indwelling catheters
By arm2966 on
Hi and welcome to Grace. …
By JanineT GRACE … on
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on